Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > COLUMN
COLUMN
- Ichi-go Ichi-e - “One Opportunity, One Encounter”
February 20, 2013
- Our Habits Are the Nuts and Bolts of Our Destiny
January 22, 2013
- What Are Japanese Pharmaceutical Candidates Thinking?
December 18, 2012
- Mid-Level Managers Seek More Guidance and Global Opportunities from Their Senior Management at Japan’s Multinational Pharmaceutical Companies
November 19, 2012
- Leading from Afar
October 22, 2012
- “Make Up Your Own Mind? What It Takes to Win Over Top-Tier Japanese Employees”
September 18, 2012
- Our Habits Determine Our Success
August 8, 2012
- Marketing Is More than a Pen and a Tissue Box
July 9, 2012
- Science without Works Is Dead
June 4, 2012
- Social Networking in Japan’s Pharmaceutical Industry
May 1, 2012
- The Eight Characteristics of a Great Leader
April 2, 2012
- Maurer’s Healthcare Insight (143)
March 26, 2012
- Maurer’s Healthcare Insight (142)
February 27, 2012
- Maurer’s Healthcare Insight (141)
January 30, 2012
- Maurer’s Healthcare Insight (140)
December 26, 2011
- Maurer’s Healthcare Insight (139)
December 12, 2011
- Maurer’s Healthcare Insight (138)
November 21, 2011
- Maurer’s Healthcare Insight（137）
October 17, 2011
- Maurer’s Healthcare Insight (136)
September 12, 2011
- Maurer's Healthcare Insight (135)
August 15, 2011
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…